A Randomized Blinded Prospective Trial Comparing PEG 3350 (MiraLAX®) with Bisacodyl Pretreatment versus PEG 3350 (MiraLAX®) with Lubiprostone Pretreatment versus PEG 3350 (MiraLAX®) without Pretreatment versus PEG 3350 (Golytely®) for Bowel Cleansing Prior to Colonoscopy: 2010 Presidential Poster

Michael Hjelkrem, Joel Z. Stengel, Mark Liu et al. · The American Journal of Gastroenterology · 2010

Purpose: Bowel preparation is paramount to ensuring a successful colonoscopy. While a clean colon makes for ideal polyp detection rates, a poor bowel preparation leads to increased medical costs, larger lesion miss rates, and longer procedure times. Recently, Polyethylene Glycol (PEG) 3350 (MiraLAX®) in combination with 64 oz Gatorade® has been gaining popularity as a bowel preparation regimen. However, there have not been any published trials on the efficacy of this bowel preparation compared to standard bowel preparations. We compared PEG 3350 (Golytely®) preparation at split-dosing to MiraLAX® alone and the combinations of MiraLAX® plus lubiprostone and MiraLAX® plus bisacodyl to determine the efficacy, patient tolerability, and patient satisfaction. Methods: Patients were randomized to receive one of four different bowel preparations: MiraLAX® without pretreatment, MiraLAX® with bisacodyl (10 mg) pretreatment, MiraLAX® with lubiprostone (24 μg) pretreatment, or Golytely® without pretreatment. MiraLAX® was combined with 64 oz of Gatorade® for bowel preparation regimens. All patients were surveyed prior to the colonoscopy on the satisfaction and tolerability of the bowel preparation. The Ottawa bowel preparation scale was used to grade the cleanliness of the colon by the endoscopist. Results: To date, statistical analysis was completed on 375 patients (92% of target enrollment). Split-dose Golytely® was found to be more effective at bowel cleansing (average Ottawa prep score 5.4) compared with split-dose MiraLAX® alone (average Ottawa prep score 6.6, p<0.002) or in combination with either lubiprostone pretreatment (average Ottawa prep score 6.2, p<0.001) or bisacodyl pretreatment (average Ottawa prep score 6.8, p<0.02). Upon statistical analysis of currently available results, 224 patients (54% of target enrollment), there was a trend toward longer colonoscopy procedure times in the MiraLAX® treatment groups compared to the Golytely® group (p=0.067). Patients enrolled in any of the three MiraLAX® treatment arms rated the overall experience as more satisfactory than the Golytely® arm (p<0.001). No differences were observed in polyp detection rates between the four groups. Conclusion: To date, cohort analysis shows that split-dose MiraLAX® is inferior to split-dose Golytely® for bowel cleansing prior to colonoscopy. Further assessment of the study cohort is necessary to determine a difference in procedure times and polyp detection rates.

Cited by 0 works. doi:10.14309/00000434-201010001-00375

Authors